hydroxyurea has been researched along with Stomach Neoplasms in 16 studies
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) in combination with hydroxyurea (HU) or 2'-deoxyguanosine (GdR) on human gastric carcinoma MK-1 cells and colon carcinoma HT-15 cells was studied." | 7.68 | Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro. ( Kamiguchi, H; Kawahara, T; Matsumoto, M; Ohkubo, T; Tsuda, M; Yamamura, M, 1992) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 6.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "The cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) in combination with hydroxyurea (HU) or 2'-deoxyguanosine (GdR) on human gastric carcinoma MK-1 cells and colon carcinoma HT-15 cells was studied." | 3.68 | Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro. ( Kamiguchi, H; Kawahara, T; Matsumoto, M; Ohkubo, T; Tsuda, M; Yamamura, M, 1992) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 2.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| " Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay." | 2.69 | Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. ( Berkenblit, R; Damle, S; Haynes, H; Kaleya, R; Ladner, RD; Murgo, A; Schechner, R; Wadler, S, 1999) |
| "He had no evidence of recurrence of gastric cancer, although he had a continuous poor appetite due to TS-1." | 1.36 | [Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer]. ( Imai, T; Machida, T; Shima, Y; Uemura, Y, 2010) |
| "Previously, we reported that a gastric cancer cell line, SNU-719, that is naturally infected with EBV closely resembles EBVaGC." | 1.35 | Maintenance of the viral episome is essential for the cell survival of an Epstein-Barr virus positive gastric carcinoma cell line. ( Kim, M; Lee, SK; Oh, ST, 2009) |
| "Acute myeloid leukemia was finally diagnosed in October 1998, and chromosomal analysis disclosed inv(3) in addition to -5 and -7." | 1.31 | [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. ( Aoki, K; Chiba, S; Hirai, H; Honda, H; Horikoshi, M; Itikawa, M; Kurokawa, M; Machida, U; Masuda, S; Mitani, K; Ogawa, S; Seo, S; Sunaga, S; Yazaki, Y, 2000) |
| "The growth of the human gastric cancer cell line HGT-1 is regulated by a gastrin-like peptide through an autocrine process." | 1.29 | [Study of S phase synchronization of the human gastric cancer line HGT-1]. ( Bali, JP; Duperray, C; Rémy-Heintz, N, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, J | 1 |
| Zhang, C | 1 |
| Lin, J | 1 |
| Duan, P | 1 |
| Long, J | 1 |
| Zhu, H | 1 |
| Chen, G | 1 |
| Chen, J | 1 |
| Qiao, Y | 1 |
| Shi, Y | 1 |
| Liu, W | 1 |
| Zeng, Q | 1 |
| Xie, H | 1 |
| Shi, X | 1 |
| Sun, Y | 1 |
| Liu, X | 1 |
| Li, T | 1 |
| Zhou, L | 1 |
| Wan, J | 1 |
| Xie, T | 1 |
| Wang, H | 1 |
| Wang, F | 1 |
| Song, MJ | 1 |
| Oh, ST | 1 |
| Kim, M | 1 |
| Lee, SK | 1 |
| Uemura, Y | 1 |
| Imai, T | 1 |
| Machida, T | 1 |
| Shima, Y | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 1 |
| Kaubisch, A | 1 |
| Kaleya, R | 2 |
| Haynes, H | 2 |
| Rozenblit, A | 1 |
| Wadler, S | 2 |
| Lerner, H | 1 |
| Marcovitz, E | 1 |
| Zaren, H | 1 |
| Rémy-Heintz, N | 1 |
| Duperray, C | 1 |
| Bali, JP | 1 |
| Damle, S | 1 |
| Schechner, R | 1 |
| Berkenblit, R | 1 |
| Ladner, RD | 1 |
| Murgo, A | 1 |
| Horikoshi, M | 1 |
| Machida, U | 1 |
| Itikawa, M | 1 |
| Seo, S | 1 |
| Masuda, S | 1 |
| Kurokawa, M | 1 |
| Ogawa, S | 1 |
| Sunaga, S | 1 |
| Honda, H | 1 |
| Aoki, K | 1 |
| Chiba, S | 1 |
| Mitani, K | 1 |
| Hirai, H | 1 |
| Yazaki, Y | 1 |
| Hartenstein, R | 1 |
| Ertl, E | 1 |
| Possinger, K | 1 |
| Ehrhart, H | 1 |
| Wollner, N | 1 |
| Lieberman, P | 1 |
| Exelby, P | 1 |
| D'angio, G | 1 |
| Burchenal, J | 1 |
| Fang, S | 1 |
| Murphy, ML | 1 |
| Matsumoto, M | 1 |
| Kawahara, T | 1 |
| Tsuda, M | 1 |
| Ohkubo, T | 1 |
| Kamiguchi, H | 1 |
| Yamamura, M | 1 |
| Moertel, CG | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
3 trials available for hydroxyurea and Stomach Neoplasms
| Article | Year |
|---|---|
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2004 |
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxyurac | 1999 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
13 other studies available for hydroxyurea and Stomach Neoplasms
| Article | Year |
|---|---|
ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.
Topics: Analysis of Variance; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Proliferation; Cell S | 2021 |
ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Binding Sites; Camptothecin; | 2018 |
Maintenance of the viral genome may be the Achilles' tendon for virus-associated cancer.
Topics: Carcinoma; Cell Proliferation; Cell Survival; Cell Transformation, Viral; Epstein-Barr Virus Nuclear | 2009 |
Maintenance of the viral episome is essential for the cell survival of an Epstein-Barr virus positive gastric carcinoma cell line.
Topics: Blotting, Southern; Carcinoma; Cell Proliferation; Cell Survival; Cell Transformation, Viral; Dose-R | 2009 |
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Hu | 2010 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Gastric cancer-survival at the Pennsylvania Hospital with and without adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Gas | 1983 |
[Study of S phase synchronization of the human gastric cancer line HGT-1].
Topics: Adenocarcinoma; Flow Cytometry; Humans; Hydroxyurea; Middle Aged; S Phase; Stomach Neoplasms; Thymid | 1993 |
[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair | 2000 |
[Influence of hydroxyurea on DNA synthesis of human bone marrow in vivo (author's transl)].
Topics: Adult; Bone Marrow; DNA; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Stomach Neoplasms; Testic | 1979 |
Non-Hodgkin's lymphoma in children: results of treatment with LSA2-L2 protocol.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Child; Child, Preschool; Cyclophosp | 1975 |
Synergistic inhibition of human gastric carcinoma cell growth by 1-beta-D-arabinofuranosylcytosine and hydroxyurea or 2'-deoxyguanosine in vitro.
Topics: Carcinoma; Cell Death; Cell Division; Colonic Neoplasms; Cytarabine; Deoxyguanosine; Deoxyribonucleo | 1992 |
Cancer of the gastrointestinal tract. Chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Carmustine; Cyclohexanes; Cyclophosphamide; Drug Therapy, Combi | 1974 |